Zobrazeno 1 - 10
of 56
pro vyhledávání: '"M Klasser"'
Publikováno v:
Basal Ganglia. 5:101-106
Rasagiline (Azilect®) is a highly selective irreversible second generation MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy or as adjunct therapy (with levodopa). The 6-month observational study inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0efcde7d1d873545a246f23a61b8ee90
https://doi.org/10.1016/j.baga.2015.09.003
https://doi.org/10.1016/j.baga.2015.09.003
Publikováno v:
Supportive Care in Cancer
The study aims to assess the relative efficacy of granulocyte colony-stimulating factor (G-CSF) products administered as primary prophylaxis (PP) to patients with cancer receiving myelosuppressive chemotherapy.A systematic literature review identifie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f6056340ba781e1eb4fbe3d0f1c8758
https://doi.org/10.1007/s00520-016-3116-3
https://doi.org/10.1007/s00520-016-3116-3
Publikováno v:
Aktuelle Neurologie. 36:55-59
Rasagiline (Azilect®) is a potent, highly selective, irreversible second generation MAO-B inhibitor and is indicated for treatment of idiopathic Parkinson's disease (iPD) as monotherapy (without levodopa) or adjunct therapy (with levodopa). The pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::058c4776dd77f8ccf4b78c4779b60f09
https://doi.org/10.1055/s-0028-1090181
https://doi.org/10.1055/s-0028-1090181
Publikováno v:
Fortschritte der Neurologie · Psychiatrie. 76:594-599
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f9d0f33f03b060fa6c4c97b4a6d1d94
https://doi.org/10.1055/s-2008-1038249
https://doi.org/10.1055/s-2008-1038249
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 43:420-428
UNLABELLED Between 1997 and 2002, a post-marketing surveillance study was conducted throughout Germany to evaluate Intraglobin F in a replacement therapy for primary and secondary immunodeficiency diseases. A total of 15,548 individual administration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b38fb60fb1bf4bc1f4d00946ce8675
https://doi.org/10.5414/cpp43420
https://doi.org/10.5414/cpp43420
Autor:
M. Klasser, H. Reichel
Publikováno v:
Nieren- und Hochdruckkrankheiten. 32:331-341
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::167497610e9015676ff6f6282fbe6d50
https://doi.org/10.5414/nhp32331
https://doi.org/10.5414/nhp32331
Autor:
H Rolinger, H W Bauer, M Klasser, G Schladitz, H D Henke, K L von Hanstein, K Steinbach, W Gimbel
Publikováno v:
Clinical Rheumatology. 18:4-9
In this multicentre (five centres in Germany), randomised, double-blind, comparative study, 150 patients with painful degenerative joint disease according to EULAR criteria received either oxaceprol (200 mg three times daily) or diclofenac (25 mg thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05577ea3d27015531e85455a1bd55a17
https://doi.org/10.1007/s100670050043
https://doi.org/10.1007/s100670050043
Publikováno v:
Klinische Neurophysiologie. 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0b1faa356903ba5163caa0a314c743c
https://doi.org/10.1055/s-0030-1250831
https://doi.org/10.1055/s-0030-1250831
Publikováno v:
Fortschritte der Neurologie-Psychiatrie. 76(10)
Rasagiline (Azilect) is a potent, highly selective and irreversible inhibitor of monoamine oxidase type B of the second generation. Rasagiline is indicated for the treatment of Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74cec5cb7d5e2a36b736d1658eb61213
https://pubmed.ncbi.nlm.nih.gov/18833504
https://pubmed.ncbi.nlm.nih.gov/18833504
Publikováno v:
Caries research. 42(4)
There is only little information on the remineralising capability of regularly applied highly concentrated fluoride gels. The aim of this in situ study was to test the hypothesis that weekly application of a 1.25% fluoride gel results in a significan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deaefc71339257944efe2654ca0f4bf7
https://pubmed.ncbi.nlm.nih.gov/18663301
https://pubmed.ncbi.nlm.nih.gov/18663301